Division of Boston Scientific Corp.
Latest From Protherics PLC
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
Contingency payments based on regulatory and sales milestones for lead emphysema product RePneu could double the price BTG pays for U.S. biotech PneumRx, the latest addition to the United Kingdom company’s interventional medicines business.
Contingency payments based on regulatory and sales milestones for lead emphysema product RePneu could double the price BTG pays for U.S. biotech PneumRx, the latest addition to the U.K. company’s interventional medicines business.
The specialist-focused health care company is building a multi-asset interventional medicines business, including multiple drug-device combination products, which it expects will grow from $150 million in annual sales to more than $1 billion by fiscal 2021.
- Large Molecule
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
- Contact Info
Phone: (44) 20 7246 9950
3 Creed Court, 5 Ludgate Hill
London, EC4M 7AA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.